On 17 july, the hunan public resource centre issued a circular on price correction of the internet-based drugs (first batch in 2024), in which 234 drugs clearly not meeting the price management requirements of hunan province were publicized。
The daily people's daily health client, a journalist, found that in hunan's list of price corrections, there was a marked reversal of prices in a number of different plant varieties. For example, 10 grams of granules are sold for a bag of $1. 365, while 3 grams are packaged for $4. 15 per bag. The same can be said for pediatric cuisine reheating particles, sodium sulfin injection, etc。
On the whole, most of the drugs in hunan for which price correction has been made have a relatively small price difference, with only a few unrated medicines having a much higher network price than evaluated, reference preparations, such as the injection of clinicillin phosphate, with 0. 6 grams of specifications of $39. 45 per dose, with a minimum of 1. 87 doses. There is also a large gap between tramadol hydrochloric acids, with the price of 0. 1 g a dose being 128 and 105 yuan, while the lowest price for a drug is 49. 5 yuan. For these products, hunan will set strict price limits on a case-by-case basis on the basis of the lowest price of the drug or reference formulation. According to the circular on price correction of the internet-based drugs (first batch in 2024), as of 26 july, companies could complain about the price limit of the anti-pharmaceutical drugs, the outcome of which was determined by the hunan health insurance board's opinion。
“as a result of price correction, the prices of medicines return to a reasonable range, and competition among enterprises will become more intense, but it will also lead to a shift in the focus of enterprises towards product innovation and improvement in the quality of services, prompt pharmaceutical enterprises to increase their investment in research and development, promote the development of new medicines and technological innovation, and thus contribute to the continued healthy development of the pharmaceutical industry.” on 20 july, the deputy director of the china investment promotion and development association (cida) general health industry commission (chai) stated that, at another level, pharmaceutical companies would be encouraged to move from simply pursuing high prices to focusing on the clinical value and social benefits of medicines, and promoting industry resources in favour of the development of efficient, safe and economical medicines. For patients, the financial burden has been reduced to a certain extent and the experience of medical services has been enhanced。
